MA46099A - Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial - Google Patents

Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial

Info

Publication number
MA46099A
MA46099A MA046099A MA46099A MA46099A MA 46099 A MA46099 A MA 46099A MA 046099 A MA046099 A MA 046099A MA 46099 A MA46099 A MA 46099A MA 46099 A MA46099 A MA 46099A
Authority
MA
Morocco
Prior art keywords
compounds
treatment
diseases associated
mitochondrial dysfunction
mitochondrial
Prior art date
Application number
MA046099A
Other languages
English (en)
Inventor
Antoine Danchin
Patrice Garnier
Agnieszka Sekowska
Original Assignee
Amabiotics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amabiotics filed Critical Amabiotics
Publication of MA46099A publication Critical patent/MA46099A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046099A 2016-08-30 2017-08-30 Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial MA46099A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306094.0A EP3290039B1 (fr) 2016-08-30 2016-08-30 Composés pour traiter des maladies associées à un dysfonctionnement mitochondrial

Publications (1)

Publication Number Publication Date
MA46099A true MA46099A (fr) 2019-07-10

Family

ID=56896495

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046099A MA46099A (fr) 2016-08-30 2017-08-30 Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial

Country Status (15)

Country Link
US (2) US10857135B2 (fr)
EP (2) EP3290039B1 (fr)
JP (1) JP7065854B2 (fr)
KR (1) KR20200011927A (fr)
CN (1) CN110035758B (fr)
AU (1) AU2017317651B2 (fr)
BR (1) BR112019004236A2 (fr)
CA (1) CA3034694A1 (fr)
ES (1) ES2800917T3 (fr)
MA (1) MA46099A (fr)
MX (1) MX394782B (fr)
RU (1) RU2019108824A (fr)
SG (1) SG11201901689YA (fr)
WO (1) WO2018041919A1 (fr)
ZA (1) ZA201900997B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2800917T3 (es) * 2016-08-30 2021-01-05 Amabiotics Compuestos para tratar enfermedades asociadas con una disfunción mitocondrial
EP3761987A1 (fr) * 2018-03-07 2021-01-13 Amabiotics Composés pour le traitement de la maladie d'alzheimer
AU2020215036A1 (en) * 2019-01-29 2021-08-12 Holobiome, Inc. Methods and compositions for treating and preventing CNS disorders and other conditions caused by gut microbial dysbiosis
EP4028014A1 (fr) * 2019-09-12 2022-07-20 Stellate Therapeutics Composés pour le traitement de maladies neurodégénératives
WO2021048431A1 (fr) * 2019-09-12 2021-03-18 Amabiotics Composés pour le traitement de l'ataxie
CN116850191A (zh) * 2023-06-16 2023-10-10 山东大学齐鲁医院 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936615A (ja) * 1982-08-24 1984-02-28 Takeda Chem Ind Ltd 発がん予防剤
WO1996033703A2 (fr) * 1995-04-25 1996-10-31 Oridigm Corporation Regulation de la s-adenosyl methionine des voies metaboliques et application au diagnostic et a la therapie
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
FR3002139B1 (fr) * 2013-02-21 2015-06-19 Amabiotics Utilisation cosmetique de la queuine
GB201417163D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
ES2800917T3 (es) * 2016-08-30 2021-01-05 Amabiotics Compuestos para tratar enfermedades asociadas con una disfunción mitocondrial

Also Published As

Publication number Publication date
JP2019526634A (ja) 2019-09-19
RU2019108824A (ru) 2020-10-01
US20210046056A1 (en) 2021-02-18
EP3290039A1 (fr) 2018-03-07
JP7065854B2 (ja) 2022-05-12
CN110035758A (zh) 2019-07-19
US10857135B2 (en) 2020-12-08
WO2018041919A1 (fr) 2018-03-08
MX2019002369A (es) 2019-11-07
US20190224174A1 (en) 2019-07-25
BR112019004236A2 (pt) 2019-05-28
SG11201901689YA (en) 2019-03-28
AU2017317651B2 (en) 2022-12-15
EP3506903A1 (fr) 2019-07-10
CN110035758B (zh) 2023-06-16
ZA201900997B (en) 2020-05-27
MX394782B (es) 2025-03-24
ES2800917T3 (es) 2021-01-05
EP3290039B1 (fr) 2020-03-25
RU2019108824A3 (fr) 2020-12-31
AU2017317651A1 (en) 2019-03-07
US11684611B2 (en) 2023-06-27
KR20200011927A (ko) 2020-02-04
CA3034694A1 (fr) 2018-03-08

Similar Documents

Publication Publication Date Title
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45192A (fr) Traitement d'association
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
MA41449A (fr) Polythérapies pour le traitement de cancers
MA50409A (fr) Polythérapies pour le traitement du cancer
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
MA48637A (fr) Polythérapies pour le traitement du cancer
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
EP3463341A4 (fr) Immunomodulateurs à base d'aminocylindazole pour le traitement de maladies auto-immunes
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3419639A4 (fr) Vecteur aav-idua pour le traitement de la cécité associée à la mps i
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies